Putao Cen is an Oncology physician. OpenAlex indexes 87 publications with 1,046 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6400 Fannin St
2900
Houston, TX 77030
Telephone
713-704-3961Provider last certified this registry record 14 Nov 2023.
Clinical trials
- Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
Sponsor: The University of Texas Health Science Center, Houston
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year202530 payments$50,963openpaymentsdata.cms.gov ↗
- TAIHO ONCOLOGY, INC.Program year202522 payments$43,998openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year202519 payments$32,716openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.8%Cytochrome P450 17A1 Inhibitor20.5%Abiraterone Acetate100%Part D≥26 patientsKinase inhibitor10.7%Lenvima71%Imatinib Mesylate29%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
34.4%Serotonin-3 Receptor Antagonist12.2%Ondansetron Hcl100%Part D≥52 patientsCorticosteroid11.5%Prednisone100%Part D≥29 patients+ 2 more classes in this area
Nervous system
7.6%Phenothiazine3.6%Prochlorperazine Maleate100%Part D≥25 patientsGabapentinoids2.6%Gabapentin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation
Journal of Investigative Medicine High Impact Case Reports
2024 - Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
Journal of Investigative Medicine High Impact Case Reports
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”